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TRANSCRIPT

HEALING APPALACHIA: KEYNOTE
DISCUSSION
Eric Eyre
Patrick C. McGinley
Becky Jacobs, Moderator
INTRODUCTION:
Welcome to "Healing
Appalachia, The Role of Professionals in Solving the
Opioid Crisis." My name is Michael Deel. On behalf of
the Tennessee Journal of Law and Policy and the
University of Tennessee College of Law, thank you for
attending.
Today we have gathered experts who are working
to find legal and political solutions to this public health
crisis while also working with individuals who are
suffering on a day-to-day basis. I invite you to not only
listen to their stories but to learn from them and to
remember their efforts when you make your own
everyday decisions, decisions like how to help a friend,
how to effect policy, how to find hidden information, or
simply how to vote in the next election.
I would like to thank all the panelists and
moderators that are participating today and also thank
everyone who helped put this event together. So many
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people gave their time and energy to make this
symposium possible.
Mr. Eric Eyre and Professor Patrick McGinley will
deliver our keynote address which will be followed by two
panel discussions and a documentary viewing. We will
take a 15-minute break between each session and there
will be a transcript available after we get it published in
the next issue of TJLP.
Mr. Eyre won the Pulitzer Prize for investigative
reporting for his articles regarding the distribution of 750
million prescription pills in West Virginia and the tragic
overdoses that followed those pills. He currently works
as a statehouse reporter for the Charleston GazzetteMail.
Professor McGinley is a Charles H. Hayden II
Professor of Law at West Virginia College of Law.
Professor McGinley teaches administrative law,
environmental law, and appellate advocacy. He also
represented the Charleston Gazzette-Mail in a lawsuit
that resulted in a court order unsealing the documents
that led to Mr. Eyre's articles.
Professor Becky Jacobs from the University of
Tennessee College of Law will moderate this discussion.
Please join me in welcoming them.
MS. JACOBS:
So just to like frame our
discussion this afternoon, I want to give you just a few
facts. So opioid painkillers are a nine-billion-dollar-ayear market in the U.S. alone. In pharmaceutical
companies such as Purdue Pharma, Johnson & Johnson,
Teva, and Allergan have all earned many billions over
the years from the sale of these drugs. Wholesaler
distributors like McKesson, Cardinal Health, and
AmerisourceBergen also have profited, as have the
physicians and pain clinics that prescribe these
medications, some legitimately, some not so legitimately.
These profits, though, have had a very, very high
public health cost as the work of our guests today helped
[286]
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to expose. According to the CDC, from 1999 to 2016, more
than 200,000 people have died in the U.S. from overdoses
related to prescription opioids.
That's just the
prescription opioids. In 2016 alone, more than 46 people
every day have died from overdoses involving
prescription opioids. Also in 2016, three of the five states
with the highest rates of death due to drug overdoses
were close to us: West Virginia had 52 per 100,000, Ohio
had 39.1 per 100,000, and Kentucky had 33.5.
Tennessee's rate was 24.5. And our guests today fought
to make these data public. So I want to thank them very
much for being here.
I want to start by asking you, for those who aren't
familiar with kind of what these drugs are, can you
describe the specific painkillers that we're talking about
and which ones are the focus of this investigation?
MR. EYRE:
Sure. The two that we primarily
focused on, because we got the DEA data on were
hydrocodone, which is Lortab and Vicodin, and
oxycodone, which is OxyContin. And there's plenty of
other pills that are distributed, but those were the two
that we focused on primarily.
MS. JACOBS:
Okay. So how you did you get
interested in the topic, and how and when did Pat get
involved?
MR. EYRE:
I kind of wound up in it in a
different way. I covered the legislature for West Virginia,
so I'm based at the Capitol, and we had a new attorney
general elected in our state. There had been a lawsuit
filed about six months prior to his win by our former
attorney general, and that lawsuit was against the drug
wholesalers. When our new attorney general got elected,
I got this phone call that this woman wanted to meet with
me outside the Capitol; she had some information for me.
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She brought this envelope of stuff. She had— I
remember it was crazy because she had a dog with her
named Bernard the Pekinese. So she's literally handing
stuff out and I'm worried I'm going to get bit by this dog,
Bernard the Pekinese. What it was was information
about the new incoming attorney general's ties to these
drug wholesalers. The one company that you mentioned,
Cardinal Health, had paid for his inauguration, and then
when we also looked back at contributions, a lot of these
drug wholesalers after the lawsuit was filed in July of
2012 had given money to the attorney general. And so
we did a story about that and he said over and over that
he had recused himself from the case at the beginning of
when we assume he took office, but we had heard from
staff that that wasn't the case. So we actually filed a
number of Freedom of Information Act requests and that
wound up in court.
This photo here is— the attorney general is on the
right there. This was a photo taken by a New York Times
reporter, Eric Lipton, who actually won the Pulitzer Prize
two or three years ago and he was writing about both the
Republican Attorneys General Association and the
Democratic Attorneys General Association wining and
dining various attorneys general to get them— to try to
persuade them to drop lawsuits or not file lawsuits. And
the woman there is Pam Bondi. I believe she's still the
attorney general in Florida.
And the story was about her being pushed— this
was in the Hotel del Coronado in San Diego, a beautiful
resort there— she was being pushed to drop a lawsuit
against 5-hour ENERGY. And these guys are lobbyists.
I think it was something like three thousand dollars a
night to stay there. I met the reporter at the Pulitzer
ceremony. And eventually when they found out what he
was doing, he got kicked out of course but . . . So the next
step was the FOIA lawsuit, and maybe Pat can talk a
little bit about that. This is back in 2013, 2014.

[288]
5
4

HEALING APPALACHIA: KEYNOTE DISCUSSION
13 TENN. J.L. & POL’Y 285 (2018)

MR. MCGINLEY: Yeah. So—
MS. JACOBS:
little bit and—
MR. EYRE:
MS. JACOBS:
McGraw filed.

Before you do that, step back a
The lawsuit—
—the first lawsuit that Darrell

MR. MCGINLEY: So in was it 2012 a long-time
West Virginia attorney general, Darrell McGraw, filed
the first case against drug distributors of opioid drugs,
recognizing the impact of opioids in West Virginia, and,
really, the first public official to take some kind of action.
The lawsuit, the cause of action, was new and it was
suggested that this is a looser, the attorney general's
office is up against Big Pharma, billion-dollar
enterprises, lawyers from New York and Philadelphia
and Cleveland. But that lawsuit was filed. And then in
a very narrow election, Attorney General McGraw lost to
Patrick Morrisey. He's pictured there in blue jeans with
a lobbyist and the attorney general of Florida. And so
within six months of the time that these "pill mill" cases,
that's what they were referred to, were filed in the
summer of 2012, a new attorney general who had
formerly been a lobbyist for trade associations from the
pharmaceutical industry took office.
MR. EYRE:
And what I forgot to mention, his
wife was the lead lobbyist for Cardinal Health in
Washington D.C. and made millions of dollars.
MR. MCGINLEY: Cardinal Health being one of
the three leading opioid drug distributors in the country.
And she continued to be a lobbyist until after our lawsuit.
There was an ethics complaint filed against the attorney
general at some point and said, well, I don't have to do
[289]
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this but I won't have my fingers on any of these cases.
But that took a couple of years. In the meantime, Eric
and the Gazzette-Mail are interested in what this new
attorney general was going to do in terms of supervising
these "pill mill" cases, considering his former relationship
with the industry. And Eric filed several FOIA requests
and he was basically stonewalled, the responses didn't
meet the requirements of the West Virginia Freedom of
Information Act. I think the first one, they said, well, if
we had these documents you're requesting that relate to
whether the attorney general is supervising the "pill mill"
cases, if we have them, they would be exempt.
And, you know, at that point the Gazzette asked
me to be of assistance, because I've done a lot of FOIA
stuff, and so I wrote to the attorney general and I said,
well, that's not good enough, you've got to look for it, you
can't just say if you have it. And then there was a series
of back and forth with nonresponsive answers from the
attorney general, and I would say, well, let's read the law,
you know, you must have something.
And then,
ultimately, after about six months, they said— they
called Eric and said, okay, you can come and look at the
documents but they are totally redacted and you can't
take photographs, and they set a time for it. And we
talked and we responded, that's not what the law
requires, no, we're not doing that. And they said, we'll
get back to you.
They didn't get back to us. We filed a FOIA suit.
It went on for almost a year. We did discovery. We found
out they had documents that they hadn't mentioned
before but they claimed were attorney-client privilege,
work product. And we thought we had a really good
paper trail, a good case for joint motions for summary
judgment, cross motions for summary judgment. And the
judge ruled against us and granted summary judgment.
And I was depressed. I thought this is a winner. Eric
and the others at the Gazzette were taken aback. And
then something happened that was interesting.
[290]
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MR. EYRE: So after we lost the FOIA case,
somebody— I was not home. This is a recreated—
actually I found this— this is actually the envelope that
it came in but somebody walked up to our house and my
son texted me at work and said some man just came up
to our house and dropped something in the mailbox with
your name on it.
Go to the next slide. You can't see it there but that
was one of the e-mails that was being withheld, and what
it said in the e-mail was that the attorney general has
specific instructions regarding this case. So it was hard
to believe— he had done multiple interviews, not just
with me but with other media, over and over again saying
that he was completely recused from the case, he had had
nothing to do with it since the day he took office. And
this countered his assertions for sure. And then where
do you want—
MR. MCGINLEY: Well, so Eric wanted to write
about this of course—
MR. EYRE:

Oh yeah.

MR. MCGINLEY: —because this is exactly the
opposite of what the attorney general had stated in court
proceedings. And so, Eric, you can tell the story. As
reporters usually would do, you asked him for comment.
MR. EYRE:
Yeah. They required all their
questions to be e-mailed, so I e-mailed a bunch of
questions about when you said that you recused yourself
from the case, it would seem this contradicts what you
are saying. We also found at around the same time there
had been some documents saying that a court hearing
related to this drug distributors lawsuit had to be
canceled because Attorney General Pat Morrisey can't fit
it into his schedule and can't make it. And so if he was
[291]
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recused from the case, why would they be saying he
couldn't be there and things like that. So I e-mailed to
their press person these questions about what's going on.
And then the next thing you know, their general counsel
called or e-mailed you, Pat.
MR. MCGINLEY: Their solicitor general.
MR. EYRE:

Became solicitor general.

MR. MCGINLEY: We never had a solicitor
general in West Virginia but it sounds like a good title.
Yeah, he called me, and I was actually here in Knoxville,
at the time I was on my way to the Public Interest
Environmental Law Conference, and I get the call on my
cell phone from Misha—
MR. EYRE:

Misha Tseytlin.

MR. MCGINLEY: —Tseytlin.
MR. EYRE:
Wisconsin.

He's now the solicitor general at

MR. MCGINLEY: —and there were documents
that were in the files of the court in our FOIA case that
were produced by (inaudible) and that were examined by
the court, quashed by the court in camera before it
granted summary judgment against us. And so he called
me and he said you better tell your client not to publish
this story about documents that are under seal in the
court, you're going to be sanctioned, and we're not going
to tolerate this. And, you know, I'm in the rental car
and—
MR. EYRE:

And I'm like am I going to jail or .

..
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MR. MCGINLEY: And I said, Misha, have you
ever heard of the Pentagon Papers case? Misha was a
law clerk to Justice Kennedy, so he knew the story. I said
you do what you want but I can assure you this is going
to go to print. But that wasn't the end of the story. We
had to have conversations with the editor and publisher
and they were concerned with are they going to sue us.
And I said they can sue you, anybody can sue you, but
this is a winner.
And they went ahead and Eric told the story. It
didn't have much impact. He continued to deny and it
just sort of went over people's heads. But we knew about
that, it was clear the relationship there. The overarching
concern was that the attorney general would somehow
dump the "pill mill" cases, that it would settle them cheap
or make errors, who knew, who knows. But he certainly
with the appearance of impropriety with his prior
relationships and the representations made to the Court,
he shouldn't have been involved at all.
MS. JACOBS:
Well, in fact, he wasn't very
aggressive about the data that you guys had to intervene
to get. So tell us about that. Because that's what broke—
MR. EYRE: That was— that was the next thing.
So if we sort of flash forward, I kind of kept following the
story and started seeing stuff in various legal filings. But
in I think it was around March 2016 we got wind that
there had been what was called a second amended
complaint or a revised complaint. When they filed the
original lawsuit back in 2012, the judge in this rural
county that was handling it said we need some specifics
here, we need some examples of, you know, this sending
these larger quantities of drugs, these "pill mill"
pharmacies. So they had filed an updated complaint
called the second amended complaint and it was filed
under seal. So this was the State of West Virginia filing
a complaint outlining its allegations against the drug
[293]
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distributors and you couldn't see it.
It was just
completely filed under seal. And I went to Pat and said,
is this possible.
MR. MCGINLEY: Yeah. I said, well, that
certainly violates the West Virginia Constitution,
violates West Virginia Freedom of Information Act, and
the West Virginia Rules of Civil Procedure. So the
general rule is that public documents should be public
when they are filed with the court. And here he had a
complaint on behalf of the State that says on behalf of the
people of West Virginia against these drug companies,
but the people don't know what the allegations are. And
so the State itself had come around to the point where it
wanted the second amended complaint to be unsealed,
but the Court did nothing and they didn't assert that
aggressively. So I talked to Eric, and I got other things
to do at the law school, and I'm thinking well they are
going to act, nothing happened, so we filed a motion to
intervene for the purposes of seeking unsealing of the
second amended complaint, which is in the materials that
you have. And we basically argued that there's no law on
the side of the drug companies.
Their response, which I think is in the material as
well, was that these are essentially trade secrets,
confidential business information about how many pills,
opioids, that we sell to pharmacies, so our competitors
would find out who the pharmacies are and how much.
And, you know, we read that and said, what? And not
only that, it was old data. And we went to Boone County
Circuit Court for a hearing. There were lawyers from
everywhere. The court was filled.
MR. EYRE:

It's a picture from the courtroom.

MR. MCGINLEY: That's our co-counsel from
Boone County, Tim Conaway. And we were totally
outnumbered. There must have been 40 lawyers there
[294]
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for the various drug companies and pharmacies. And we
argued the case. And the judge eventually said he was
going to rule to unseal the documents, and then one of
the drug companies filed a motion and wanted to have a
conference call and— what did they say—
MR. EYRE: There was like this 11th hour try to
block the release of this— to unseal this complaint and
what they said was they wanted to redact 18 words. We
had a conference call about it, and I think they filed
something too. And they said— and it was probably 70
pages long. And they said we just want to redact 18
words. They just kept saying if you can keep these 18
words out, we're good with that. Well, it turned out— I'm
making a spoiler alert here, I'm jumping ahead— but it
turned out the 18 words were 18 numbers and it was
numbers of pain pills. They said words.
MR. MCGINLEY: Yeah. And, well, the judge
didn't buy that. He ordered the complaint to be unsealed.
And then that gave Eric insight into the bigger story, the
sheer volume of opioids that were being marketed in the
places they were being marketed. When we saw that first
information, we were stunned. We're talking about a
couple hundred million doses over a five-, six-year period.
But there was more. But Eric wrote a story that was part
of the Pulitzer recognition in May of 2016. You can
describe what—
MR. EYRE: That one was some of these numbers
were— these orders were shipped— you have 20,000
oxycodone to one pharmacy in a little town of a couple
hundred people, and then it would say on the following
week they'd get another 50,000, and then the next week
they'd get another 20,000. So it was just these large
shipments over consecutive days or consecutive weeks.
And what the average hydrocodone I think nationally is
90,000 per pharmacy per year, and oxycodone is probably
[295]
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like 50,000 doses per year. So these small-town
pharmacies were getting the equivalent of what they
should have gotten in a year in a matter of a week or two.
But what ultimately happened though, where this really
opened things up, is throughout the complaint that was
unsealed, they kept referring to DEA data shows, DEA
data shows, DEA data shows this, that, and the other. So
I did a FOIA asking the attorney general's office for all
the DEA data that they used to cite all these various
figures. And it turns out that there was a 2015 e-mail
sent from DEA to the attorney general's office outlining
every shipment to every pharmacy in West Virginia of
hydrocodone and oxycodone and also it was broken down
by the name of the company and how many pills they
distributed to each county in West Virginia. And what
we— just to sum it up, after we got this DEA data, there
was a disproportionate number of pills sent to the
southern part of the state, the coalfield region.
And you had these situations where you had
pharmacies with— one town had a pharmacy— 400
people— and got nearly nine million hydrocodone pills in
two years, in just two years. There were cases like this all
over southern West Virginia, Logan County, Boone
County, Mingo County. They had a town of 3,000 in
Mingo County, they got 20 million hydrocodone over
eight years. Just these incredible numbers. And then we
looked at, you know, we did the (unintelligible) maps and
looked at where most of the overdose deaths were, and
they don't line up perfectly, but they match up pretty
closely. And these counties here, not only are they
number one for prescription drug overdose deaths in
West Virginia, but they are I think of the top 10 about six
or seven of them were all in West Virginia in the country
for overdose death rates. So it was an incredible thing.
And, in addition, I don't have a slide to show it, but the
DEA agent who sent the data to the attorney general's
office, he also did a— he mapped out the strength of the
pills of the OxyContin, the milligram levels had
[296]
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increased. So you had in 2007 the most popular milligram
level of OxyContin was five milligrams, and then the next
year it was like 10 milligrams. So the strength of the pills
were actually getting stronger too in terms of—
MR. MCGINLEY: How high did they go?
MR. EYRE: They had OxyContin 80, but that was
outlawed I believe.
MR. MCGINLEY: But they went beyond 10, it
went pretty far above it.
MR. EYRE: Yeah, I think it went to like 30.
MS. JACOBS: I know there's a quote from your
article that there were 433 pain pills for every man,
woman, and child in West Virginia.
MR. EYRE: Just those two, right. I mean, we're
not even doing hydromorphone, oxymorphone, Xanax,
and all the others.
MS. JACOBS: That's astounding.
MR. MCGINLEY: There's one parenthetical that
Eric was— when he filed actually a Freedom of
Information Act request with the attorney general
seeking the DEA data in August of 2016. And under West
Virginia law, a FOIA law response is required within five
working days. Well, the attorney general's office kept
delaying, we're looking for the data, we'll get back to you,
we'll get back to you. Meantime, there's an election going
on where the attorney general is running for re-election.
His opponent has a lot of cash and is running— has spent
several million dollars on TV ads trumpeting the
relationship of the attorney general to the drug
companies and the opioid epidemic. And there was an
[297]
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infusion of cash into Morrisey's campaign in October of—
what was it— six million dollars from the National— the
Republican Attorneys General Association, more money
that flowed from that association than any other attorney
general race. That money is sort of dark money. The
contributors are the Koch brothers, pharmaceutical
companies. And so the attorney general continued to
delay responding. And what happened then?
MR. EYRE: Pat came up with a good idea that we
should file a FOIA asking them— because they kept
responding that they are searching for the records, they
are searching for the records, and they would just keep
every five days saying we're still searching for the
records— Pat came up with an idea just to do a FOIA
saying any documents that would show you're actually
searching for the records. Of course there were none. And
then about two or three weeks before the election he did,
to his credit, he did release the DEA data.
The backdrop, as Pat was describing, was this
immense pressure in terms of ads from the democratic
opponent. Actually, CBS News had picked up on our story
and came to West Virginia multiple times. And the
attorney general agreed to do an interview with CBS
News, which I can't— I don't know who told him to do
that. But of course they did the things where they are
asking all these happy questions and then they say what
about your wife works for Cardinal Health and you have
this lawsuit and, you know, they zero in on your face and
you start seeing the twitches and all that. Well, the
democratic guy that was running against him just kept
running that interview over and over in his ad. But that
was countered by all the money from the Republican
Attorneys General Association who said that the
democratic opponent was big friends with Hillary Clinton
and Obama and they pounded that over and over and
over, which is a simple effective message that worked.
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MR. MCGINLEY: And Attorney General Morrisey
won the election. It was close but he prevailed. I don't
know that I would give him credit because he knew that
Eric and the Gazzette were going to write stories and we
were considering a lawsuit against him, a FOIA suit, that
would have come out right before the election. So I think
he had some good political counselors in-house that said
you better get this information out there. And it's really
a question whether that information should be— should
not be available to the public because it came from the
DEA. And that's more the problem, all this information
the DEA has but it's not shared, the public doesn't have
access to it. So the public knows because of Eric's
reporting the volume of prescription opioids that were
sold in West Virginia. But we don't know, we don't have
the data at this point, about the sales in Ohio, in New
Jersey, Tennessee, Kentucky, and so forth. And that's a
real flaw in the system. But subsequent to Eric's
reporting there have been numerous lawsuits that have
been filed here in Tennessee, for example, by
Municipalities, Indian tribes, Cities, States, against the
drug
manufacturers
and
distributors
seeking
compensation for the cost of dealing with the opioid
epidemic, which is enormous.
The American Enterprise Institute report just
came out pegging the cost to the gross domestic product
in West Virginia of eight billion dollars. That sounds high
to me but I don't know. And the human cost, you can't
calculate that. And, hopefully, in these cases that are, you
know, following up on what West Virginia did, that
litigation and exposure. But the volume— I was looking
at the audience here, we were talking about how many
oxycodone, OxyContin pills, and the total is 780 million.
And when we saw that, I said oh my God. I think that's
what a jury would do, if you've got a case where you could
get it to the jury. It's a question of creative lawyering,
having statute or common law remedies that will make
these— hold these billion-dollar companies responsible.
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And that's one of the grossest things about this whole
story is the billions of dollars that these companies have
made and there have been very few repercussions,
certainly not to the companies. Three of the top 15
Fortune 500 companies are drug distributors and were
parties in the "pill mill" litigation in West Virginia.
McKesson, Cardinal Health, Amerisource Bergen, not
household names, but they're right up there with WalMart and Apple. And what do they do? I mean, what—
MR. EYRE: They ship drugs from factories to
warehouses to pharmacies and hospitals.
MS. JACOBS: Purdue Pharma who produces
OxyContin—
MR. MCGINLEY: The manufacturer.
MS. JACOBS: —they're the manufacturer,
privately owned by a family, and they are I think the
wealthiest, or maybe behind Bill Gates, in the country.
MR. EYRE: Well, like McKesson is the number
five on the Fortune 500. And that shocked me. I didn't
even figure that all out until we were in the courtroom
and I turned around and introduced myself, and
somebody was telling me they were from D.C. and like
Cardinal Health or the other companies would have three
or four lawyers there. We don't have the rankings but I
think it's Wal-Mart, Apple is number two on the Fortune
500, or Berkshire Hathaway, Exxon, and then McKesson
is number five. And then I'm not going to get these
exactly right but I think AmerisourceBergen is 12 and
Cardinal Health is 15. And they've actually climbed—
since my story has come out, they've actually climbed in
places in the Fortune 500. These are CEOs that are
making— a guy in McKesson— there's been stories in
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Fortune or Forbes— Forbes— making over 60 million
dollars a year in compensation.
MR. MCGINLEY: The McKesson CEO one year
was the highest paid CEO of any corporation in the
United States.
MR. EYRE: And nobody had heard anything.
MS. JACOBS: I've heard another topic you've
done. You were talking about the distribution
outlets, some of the pharmacies. It wasn't Wal-Mart or
Walgreens or— tell us about where these pills were being
distributed in West Virginia.
MR. EYRE: Yeah. That was surprising. Because
before I covered the— as you guys know a lot about the
meth epidemic when they're doing the shake and bake
bottles and making it with Sudafed, and we used to
identify the pharmacies that were selling the most
Sudafed in the state and they were typically the WalMarts and the Rite Aids. But in this case it was these
independent pharmacies, these mom and pop
pharmacies. They were literally drive-thru pharmacies.
They didn't sell Band-Aids, they didn't sell Q-tips. They
literally had names like Meds To Go Express and Larry's
Drive-thru Pharmacy. And you'd see people lined up up
and down the block. People would come from all over. You
know, I've seen recent stories where some of these
pharmacies are defending themselves saying we just
didn't serve the town of 400, people came from all over.
But I think that's more damning than— I mean, they
were literally coming from Tennessee, Kentucky, Ohio,
Pennsylvania to these little small towns in the southern
part of West Virginia. Whitfield, Virginia is another
place.
And you had these— you know, I wasn't there—
but everybody describes these scenes that there's one
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pharmacy in Kermit, which is this little town of 400
people, because there were so many people in line, they
started handing out bags of free popcorn just as a bonus.
They had bags for the people in town where if it was
opioids, you'd get it in one color bag, and if not, like if it
was blood pressure medication, you'd get it in another
color bag, because they didn't want the senior citizens in
town getting robbed. Because if the people would see you
had the color bag that wasn't opioids, then they wouldn't
rob you. They actually set up a hotdog stand with
hamburgers and hotdogs while people were waiting in
line. It was just an unbelievable scene from what's been
described to me.
MR. MCGINLEY: What about the doctors? I refer
to this as a legal cartel. You have the Mexican brown
heroin cartel or Columbian cocaine cartel. You have the
legal cartel, you've got manufacturers, you've got the
distributors, you've got the doctors who were writing the
scripts, you've got the pharmacies who were filling the
prescriptions, they all had to know. With those numbers,
all of them knew. And where was the law enforcement?
Where is the Pharmacy Board? Where was the DEA? And
this was going on for more than a decade. And I think the
numbers, when we finally saw the numbers, the light
went on and the country woke up to realize that this was
all legal and they had— the defense was of the
manufacturers, well, we're just making stuff to help
people with their pain. The distributors, we're just taking
them to the pharmacies. The pharmacies, we're just
filling the doctors' prescriptions. And the doctors saying
we're helping our patients with pain. They are all
pointing fingers, they didn't do anything wrong. The
doctor's office, what was that like?
MR. EYRE: Just last week or this week they
busted what's called The Hope Clinic. I think at one point
they had— yeah, what a name for a "pill mill" pain clinic,
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The Hope Clinic, we're giving people hope— I had
actually written about them. One of the prisms of my
stories is they only focused on the drug wholesalers. My
mom called me the day that story came out, when it first
came out back in December 2016, she said what about the
doctors. And I said I've been writing about the doctors for
years. They had these pain clinics where the doctors
didn't even show up. The one that just got busted that we
wrote about back in 2014, 2015, they had former cops,
retired cops, who were taking people's blood pressure,
doing the weight, doing their charts. They carried guns
holstered at the site. They had these special machines, I
can't remember the exact name of them, but they were
these electronic machines that would crank out
prescriptions by the hundreds. They would have the
doctor’s signature on them, but they were just being
reproduced through the machines. And I would get calls
back in 2014, 2015 from legitimate pharmacists that
would call me up and say come up and let me show you
what they are doing, you know. But they would set up
special relationships with some pharmacies that were
disreputable, and they would fill those prescriptions. And
it was an all cash basis. There was no insurance or
anything like that. It was just a cash only business.
MS. JACOBS: It's astounding that— where was
the Board of Pharmacy? In your third article you talked
about the responsibility to file reports about large
shipments. What happened with all of that?
MR. EYRE: Well, our Board of Pharmacy is
almost exclusively made up of independent mom and pop,
including some that were involved in this "pill mill" stuff.
Their directors are all appointed by the governor and
they are all independent pharmacists. So they had some
rules on the books related to something called "suspicious
orders" and those are orders of large numbers of drugs
over consecutive days or massive quantities over one day.
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MR. MCGINLEY: Those are Federal rules; right?
MR. EYRE: It was a DEA rule that the State had
copied and put into their rules at the Board of Pharmacy.
And I asked our executive director of our Pharmacy
Board, because it was cited in the lawsuit, I said what are
you doing with that. They said that hasn't been on my
radar, we just don't enforce that rule. So there had been
no suspicious order reports filed by any of these drug
wholesalers before 2012. But when the lawsuit was filed
by the former attorney general, a couple of them— two of
them started sending suspicious order reports to the
Board of Pharmacy, sometimes two or three a day. I went
and said can I take a look at them. I thought they would
be cataloged, they'd have a total number or something.
And they just came— I came into the office and they came
in with two big bankers boxes full and they dropped them
on the table and they said here is all our suspicious order
reports. And I said, well, what have you done with them.
And they said we haven't done anything with them, we
just shelve them. And they hadn't cataloged them, so I
literally had to count through each one to figure out how
many had been filed.
MS. JACOBS: Were they included in the lawsuit,
the warrant?
MR. MCGINLEY: Not at that point, no.
MS. JACOBS: That's amazing. So talk a little bit
about the consequences, like the kind of after-effect. Your
work had a significant impact on all the lawsuits that
happened. And what else do you think you have done,
your work has done?
MR. EYRE: Well, the biggest development is there
is a congressional investigation in the House Energy and
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Commerce Committee and what they're doing that we
hadn't been able to do for the most part is linking up exact
numbers from each company to each of these pharmacies,
and many of them were shuttered, a lot of them are still
open actually, and they've been able to sort of dovetail or
expand upon our work. They were originally stonewalled
by the DEA. I think in some respects the Congressional
Committees were still being stonewalled. But they've
come out with some more shocking numbers like
McKesson over a two-year period they figured out of
those nine million pills like five million were from
McKesson alone, 76 percent of the business. They've
gotten some real granular detail. And they've identified
other regional wholesalers. Another name is MiamiLuken, H.D. Smith. They're starting to get more
numbers. But what's frustrating is, we talked a little bit
about this earlier, the DEA, they have all this data. I get
calls from all over the country saying can we replicate
what you did. And I said the DEA in a matter of I can't
imagine it would take more than an hour to do the
spreadsheets that we got, it's a simple sort, but they just
won't do it. They point to there's data available on their
Web site called ARCOS data but it's broken down by
grams and by zip code prefixes. Which I tried to look up
our zip code prefixes in West Virginia and they span
sometimes four or five counties or they dig into half of a
county, and it's very complicated to do it that way. There
are ways to see the overall number of grams by state,
things like that, but nothing like what we got.
MS. JACOBS: Yeah. So what do— I mean, I've
noticed—
MR. MCGINLEY: Can I add something there?
MR. EYRE: Yeah.
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MR. MCGINLEY: With regard to the DEA, some
of you may have saw the story, the DEA had an official
that was in charge of checking on the drug distributors,
you know, for suspicious orders and volumes and was
trying to organize enforcement actions, at least the story
that's been told publicly, and wasn't permitted to go
forward. I think there was pressure from higher up in the
agency or political pressure in the regional offices. But
there were people in the DEA enforcement that wanted
to do something about the enormous volume of opioids
that were being distributed. And the trade associations
for the pharmaceutical industry hired a former member
of the DEA's general counsel's office to draft legislation
that essentially took away the DEA's enforcement power.
That's the old revolving door. You know, anybody that's
been around government knows about that. And that bill
was written in language that was not penetrable by those
who don't really understand the legal terminology and
what the DEA does, and so it was sponsored by a
congressman from northeast Pennsylvania and it was
passed on a voice vote in both the House and the Senate
unanimously. I think the attorney general did raise some
question about it. President Obama signed it and
nobody— clearly, no one read it and knew what was in
there. So here is an effort funded by the industry to talk
about DEA oversight and enforcement power and it just
goes totally under the radar until the Washington Post—
was it—
MS. JACOBS: 60 Minutes.
MR. MCGINLEY: —60 Minutes last fall did this
exposé. At that time the congressman of Pennsylvania
had been nominated by President Trump to be the new
head of the DEA.
MS. JACOBS: Yeah, the drug czar.
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MR. EYRE: The drug czar.
MR. MCGINLEY: Drug czar.
MS. JACOBS: It's very interesting. It's very
Orwellian. The name of the legislation was "Ensuring
Patient Access and Effective Drug Enforcement Act".
That was the name of the legislation. It sounds really
great, so if you didn't read it, you would vote for it
thinking this is great for enforcement. But it basically—
the DEA, to take any kind of enforcement action, they
have to show a substantial likelihood of an immediate
threat. Immediate. So it's a higher bar than they ever
had. And they also cannot sanction any company unless
they allow them first to put in place a corrective action
plan.
MR. MCGINLEY: Which did not exist in the prior
legislative plan.
MS. JACOBS: Yeah. So it's a very different
enforcement regime than they had previously.
MR. MCGINLEY: A little bit of good news is the
congressman's nomination was withdrawn a few days
after the 60 Minutes show ran.
MS. JACOBS: Well, apparently, there's a lot of
outrage about it in the House and Senate, so I think
there's a move to repeal it. So, hopefully, that might
happen. I think there's a lot on the legal side, and
hopefully the next panel will talk about some of the legal
fallout from this, but I think there are over 250 public
lawsuits, you know, Cities, Counties, and State attorneys
general. I think every state either has a lawsuit pending
or they are investigating lawsuits against the opioid
industry, some faction of it. And they consolidated a lot
of those in this multi-district lawsuit in Ohio and— but
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the companies have tried to like get settlement
discussions going and to seal a lot of the data that's been
coming out of that. Interesting development I read about
yesterday, there's some lawsuits in Michigan on RICO,
which I think is a really great kind of cause of action, a
really creative theory. Hospitals have begun to sue,
which is another really interesting— looks like if the
cities can do it, we should be able to do it. Insurance
companies are probably next. And legislatively, I think
people have started— I don't know if it's happened in
West Virginia— they a resetting prescribing limits,
which I think should have been—
MR. EYRE: We have a bill pending that was just
approved by the Senate that's been turned over to the
House for seven-day. Do you guys have three-day or—
MS. JACOBS: I don't know what Tennessee is, if
we have one.
MR. EYRE: Some states have three-day, some
have five-day limits.
MS. JACOBS: And there are other— and just last
week I think, the OxyContin manufacturer, Purdue
Pharma, said they are not going to market to doctors
anymore. I'm not sure at this point that makes any
difference since they're firmly entrenched but . . .
MR. MCGINLEY: Marketing to doctors often
means paying doctors large amounts to give a talk at
some proceeding sometimes in Rome or Paris or resorts,
and it can be very lucrative for doctors and inroads to
doctors prescribing particular drugs. It's not only in the
opioid field but certainly makes a difference. Purdue
Pharma has one of the worst records in terms of they're
really marketing their opioids as not being addictive.
That was the first round. I mean, that's when the opioids
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really started to kick off, you know, doctors prescribing
them, manufacturers saying they are not addictive. Am I
right about that?
MR. EYRE: Yeah, absolutely right.
MS. JACOBS: They said it was something like
ibuprofen.
MR. EYRE: Our public health commissioner is one
of the champions at trying to reduce that the opioid
epidemic— he's really a good guy. He's like— he actually
came from Tennessee and he's like, you know, we just
were fed a bill of goods, and he's regressed and he's like I
was a big prescriber of OxyContin. When I talk about
these "pill mills", I mean, these were guys that had been
like disciplined in other states, that lost their license in
other states, and then show up in southern West
Virginia. These were bad, bad guys.
MR. MCGINLEY: Can I say just one thing about
that?
MR. EYRE: Yeah.
MR. MCGINLEY: The legal actions now that have
multiplied, I mean, they are looking for reliable legal
theory, might be RICO, might be common law, whatever,
but the thing that exists is intent and knowledge. You
can't look at those numbers and believe that this was a
legal operation. And the doctors made millions. The
pharmacies made millions. The distributors and the
manufacturers made billions. So, you know, there's the
intent, there's the knowledge. It's looking for creative
lawyers and law that would at least try to bring some
money back to the communities and try to figure out what
the solutions are. And I know you're going to be talking
about that on panels this afternoon. I mean, this is a long
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road. It's difficult. Money is important and it's just one of
the parts of the puzzle.
MS. JACOBS: So we don't have tons of time left
but do you have questions? Anybody have questions?
UNIDENTIFIED SPEAKER: I missed whether or
not you got that all unsealed or not.
MR. MCGINLEY: Yes.
MR. EYRE: Well, actually, companies that settled
previously were allowed to keep their numbers under
seal, who had settled previously with the State. But we
got most of the larger companies.
MR. MCGINLEY: The complaints in— the second
amended complaint is in the materials and it does say
redacted, that was almost wholly redacted, so we have
some of the ones that settled. The judge let them off the
hook. I think we could still get that through—
MR. EYRE: Miami-Luken was the one— probably
the one— the largest of the ones that were nonexempt.
But a lot of them are real small and didn't have large
distributions in the state. And I could see from the DEA
data that I had later which ones were, you know, larger.
We got Amerisource Bergen, we got Cardinal Health. The
McKesson case is a separate lawsuit that's still pending.
UNIDENTIFIED SPEAKER: Well, the same way
that the states sue tobacco companies, is that going on
yet?
MR. EYRE: Yeah. And one thing we haven't
talked about yet is that there's been some evidence, in
particular with McKesson and Miami-Luken, that there
were concerns brought to higher-ups, to executives, from
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regional managers, and things like that, that these
numbers were extraordinarily high. There was
something with the McKesson, there's a separate action
against McKesson by shareholders in Delaware and
there's allegations that there were actually concerns
brought by certain employees to the Board of Directors
and they didn't do anything, allegations.
MS. JACOBS: And, interestingly, one of the main
tobacco lawyers, Mike Moore, is involved in a lot of these
suits, the pharmaceutical suits, also on the plaintiff's
side. So they're getting that same coalition together to
work on these pharmaceutical cases.
MR. MCGINLEY: One of the problems with those
suits is if the plaintiffs are awarded compensation, will it
go to deal with the problem. That's one of the problems
with the tobacco suits and the lawyers— there's a lot of
good lawyers. Moore is, you know, he's effective but— and
they will make money. That’s what lawyers do. But will
the proceeds go to help solve the problem.
UNIDENTIFIED SPEAKER: I have some family
there, married into family that's from Boone County. So
I guess what I'm thinking is what now. There's all of this.
Obviously your work has exposed a lot of this. But what
is happening in West Virginia to try to help these people?
MR. EYRE: They did take the money from the
settlements and put it towards treatment beds but the
sad thing is—
UNIDENTIFIED SPEAKER: The trouble with
those towns, like when I go to visit my husband's
grandmother who is in Madison, you know, she's lived
there—
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MR. EYRE: That's where all this started, in
Madison.
UNIDENTIFIED SPEAKER: Yeah.
MR. EYRE: Everything started in Madison.
UNIDENTIFIED SPEAKER: Like I know where
Larry's is, you know, I've driven past there. There's no
one hardly left in the town, I mean, they've either moved
away, died.
MR. MCGINLEY: One of the problems is that, you
know, people who are disempowered who have lost their
jobs in the coal industry, you know, they've lived in the
area, their family has been there for generations, what do
you do. And, you know, coalminers that were injured,
they take painkillers, and it just steamrolls. And an
economy that is already going down is plagued by this
epidemic. And it's an enormous problem. I would say— I
mean, there are certainly well-meaning people
throughout West Virginia who are trying to come up with
solutions, but there's a lot of talk too and there are people
who are trying to make a profit off of the solutions.
UNIDENTIFIED SPEAKER: And not enough
money, right—
MR. MCGINLEY: Right.
UNIDENTIFIED SPEAKER: —to actually help
all the people that actually have problems?
MR. MCGINLEY: Right.
UNIDENTIFIED SPEAKER: So unless it's on a
national level—
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MR. EYRE: And the problem is it keeps shifting,
you know, it went to heroin, and then it went to Fentanyl.
And now— I was just a week-and-a-half ago in Madison
talking to Judge Thompson— you probably knew Judge
Thompson— he said now I'm seeing all this crystal meth
and cocaine overdoses. So it keeps shifting when you—
UNIDENTIFIED SPEAKER: What about the
pharmacists and the doctors, any disciplinary action,
anything happening to the people who—
MR. MCGINLEY: A little.
MR. EYRE: The pain clinic, they— but that was
like three years too late— but they finally indicted 12
doctors that were affiliated with The Hope Clinic for
something that occurred back in 2012 to 2015.
UNIDENTIFIED SPEAKER: I'm from Tyler
County. I did my undergraduate at WVU. I just recently
last summer spent the summer working with the drug
court of the Circuit of Marshall, Tyler, and Wetzel, so I've
seen first-hand the experience of the issue. Just kind of
piggybacking off of her question, it seems like the
Suboxone is becoming a replacement for the addiction. I
just wondered if you had looked into or, you know, this
could speak to that issue that we are replacing a drug
dependency with another prescription that has a high
risk of dependency.
MR. EYRE: Well, the Boone County judge has his
drug court too and he is very upset because he's directed
to do the treatment with Suboxone and they are diverting
the Suboxone. Another problem that's cropped up is
many of these "pill mill" doctors that lost their licenses
and went to jail, they are out of jail now and now they are
opening up Suboxone clinics next to legitimate, you know,
the more corporate Suboxone clinics. They're opening up
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and they are not doing any counseling, they're not doing
anything but just handing out the sublingual things that
they take.
MR. MCGINLEY: That's a really important
question. I know that there is some discussion in the
panels this afternoon. I know Suzanne Weise is here and
she's going to talk about it from her experience with the
Child & Family Law Clinic at WVU. I want to give
Suzanne the shoutout too because she was co-counsel in
the FOIA cases and in our intervention in the "pill mill"
cases. But I think that's going to come up in discussion
this afternoon.
MS. JACOBS: That's another interesting legal
consequence though. Suboxone's maker is a British
company, Reckitt Benckiser, and they actually are being
sued by 35 U.S. states for artificially inflating their prices
and for fraudulently trying to delay their patent
expiration so to prevent generics coming in. So the kind
of collateral consequences, again, you know, they are
making all this money off of the crisis and now you have
to address their bad actions because they've got a product
that everybody suddenly needs, so . . .
MR. EYRE: Yeah. The drug money that they
distributed, they did some new grants for treatment,
Suboxone people have a very strong lobby down at the
Legislature, so all faith-based, peer-to-peer type
programs were excluded from funding because they got it
written in that you had to do medication-assisted
treatment in order to qualify for funding into the grants.
You've probably seen that with the drug courts; right?
UNIDENTIFIED SPEAKER: Yeah.
MS. JACOBS: One more. I think we have time for
one more.
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UNIDENTIFIED SPEAKER: Tell us what it's like
the afternoon you get a telephone call and they tell you
you've won the Pulitzer Prize.
MR. EYRE: I was in shock for about three months.
Yeah. We're— unlike the— we're just a little-bitty paper,
30-some thousand in Charleston, West Virginia. I had
always thought when you got the Pulitzer Prize that it
was— if you've ever seen the photos in the New York
Times and Washington Post, they're standing there with
champagne bottles like they get tipped off. And then I
realized later, they didn't really get tipped off but they
just win one every year. Yeah, it was a bit crazy and . . .
I don't know. The sad end of this, and I don't want to end
on a sad note, but the numbers have continued to climb
of the overdose deaths, as yours has as well. I think yours
went up by I think 12 or 15 percent, again, because it's a
moving target. But we at least have good people on the
ground that are trying to work on it.
MS. JACOBS: Thank you for the work you've
done, and Suzanne. Thank you, guys.
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